Aesthetic plastic surgery · 2025
Concentrated Micronized Fat Ameliorates Skin Fibrosis in Bleomycin-Induced Murine Model and Enhances Fat Graft Survival.
СтатьяНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Ma Xuan, Dong Miao, Yin Ningbei, Li Facheng
Аннотация
BACKGROUND: Scleroderma is characterized by fibrosis of the skin and internal organs, vascular abnormalities, and immune dysregulation. Fat grafting has emerged as a promising therapeutic approach for improving soft tissue deficits and alleviating fibrosis in scleroderma patients. However, low fat graft survival and unresolved fibrosis in fibrotic tissues limit its efficacy. This study aims to evaluate the efficacy of Concentrated Micronized Fat (CMF), a mechanically processed fat product enriched with stromal vascular fraction (SVF) cells and intact adipocytes, in mitigating bleomycin-induced skin fibrosis and enhancing fat graft survival.
METHOD: CMF was prepared using a mechanical micronization and filtration-adsorption method to enrich stromal vascular fraction cells while retaining intact adipocytes. In vitro experiments assessed the effects of CMF on fibroblast proliferation and migration. A murine model of bleomycin (BLM)-induced skin fibrosis was established, and the therapeutic effects of CMF and Coleman fat were compared through in vivo transplantation.
RESULT: In vitro experiments showed that CMF significantly inhibited fibroblast proliferation and migration. In vivo, CMF transplantation effectively mitigated bleomycin-induced dermal thickening and collagen deposition while promoting adipocyte survival.
CONCLUSION: CMF effectively alleviates skin fibrosis. It improves fat graft retention under fibrotic conditions. These results suggest that CMF is a promising therapeutic approach for treating scleroderma-related fibrosis.
NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .
METHOD: CMF was prepared using a mechanical micronization and filtration-adsorption method to enrich stromal vascular fraction cells while retaining intact adipocytes. In vitro experiments assessed the effects of CMF on fibroblast proliferation and migration. A murine model of bleomycin (BLM)-induced skin fibrosis was established, and the therapeutic effects of CMF and Coleman fat were compared through in vivo transplantation.
RESULT: In vitro experiments showed that CMF significantly inhibited fibroblast proliferation and migration. In vivo, CMF transplantation effectively mitigated bleomycin-induced dermal thickening and collagen deposition while promoting adipocyte survival.
CONCLUSION: CMF effectively alleviates skin fibrosis. It improves fat graft retention under fibrotic conditions. These results suggest that CMF is a promising therapeutic approach for treating scleroderma-related fibrosis.
NO LEVEL ASSIGNED: This journal requires that authors assign a level of evidence to each submission to which Evidence-Based Medicine rankings are applicable. This excludes Review Articles, Book Reviews, and manuscripts that concern Basic Science, Animal Studies, Cadaver Studies, and Experimental Studies. For a full description of these Evidence-Based Medicine ratings, please refer to the Table of Contents or the online Instructions to Authors www.springer.com/00266 .